2 months ago
LLY
AnalystsSeamus FernandezSeamus Fernandez's Stock Forecasts
AnalystsSeamus Fernandez
Analyst Ranking
Top 2%
#66 out of 5116 analysts
Average Return
+73.89%
Win Rate
68%46 out of 68
Risk vs Reward
Poor
Good
Seamus Fernandez's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Cidara Therapeutics IncCDTX | +1,080.25% | $18.63 | $219.88 | 2025-05-09 - 2025-11-28 | Strong Buy |
Cidara Therapeutics IncCDTX | +762.27% | $25.50 | $219.88 | 2025-05-16 - 2025-11-28 | Strong Buy |
Cidara Therapeutics IncCDTX | +673.26% | $13.50 | $104.39 | 2024-11-08 - 2025-11-07 | Strong Buy |
Mbx Biosciences IncMBX | +450.08% | $6.27 | $34.49 | 2025-04-10 - 2025-11-28 | Strong Buy |
Cidara Therapeutics IncCDTX | +369.43% | $46.84 | $219.88 | 2025-06-24 - 2025-11-28 | Strong Buy |
Seamus Fernandez Analyst Color
Get additional color on Seamus Fernandez's coverage of popular stocks
2 months ago
CDTX
2 months ago
MBX
3 months ago
AMLX
5 months ago
CDTX
7 months ago
CDTX
7 months ago
CDTX
8 months ago
LLY
a year ago
APGE
a year ago
LLY
2 years ago
APGE
2 years ago
APGE
3 years ago
MRK
3 years ago
LLY
4 years ago
MRK
Seamus Fernandez's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Inventiva SaIVA | 1 | Strong Buy | $11.00 | +158.82% | Maintains | 14 days ago |
Mbx Biosciences IncMBX | 4 | Strong Buy | $77.00 | +123.25% | Maintains | 22 days ago |
Eli Lilly & CoLLY | 12 | Strong Buy | $948.00 | -11.85% | Reiterates | 2 months ago |
Cidara Therapeutics IncCDTX | 5 | Strong Buy | $167.00 | -24.05% | Maintains | 2 months ago |
Amylyx Pharmaceuticals IncAMLX | 2 | Strong Buy | $25.00 | +66.89% | Maintains | 3 months ago |
Tenax Therapeutics IncTENX | 2 | Strong Buy | $14.00 | +48.46% | Maintains | 4 months ago |
Structure Therapeutics IncGPCR | 2 | Strong Buy | $90.00 | +151.33% | Maintains | 4 months ago |
Rhythm Pharmaceuticals IncRYTM | 2 | Strong Buy | $120.00 | +10.00% | Maintains | 4 months ago |
Apogee Therapeutics IncAPGE | 6 | Strong Buy | $116.00 | +61.18% | Reiterates | 5 months ago |
Vaxcyte IncPCVX | 4 | Strong Buy | $160.00 | +222.52% | Reiterates | 9 months ago |
Metsera IncMTSR | 1 | Strong Buy | $56.00 | -20.57% | Initiates Coverage On | 9 months ago |
Merck & Co IncMRK | 9 | Strong Buy | $122.00 | +16.38% | Maintains | 10 months ago |
Icosavax IncICVX | 1 | Strong Buy | $28.00 | N/A | Initiates Coverage On | 2 years ago |
Hillevax IncHLVX | 2 | Strong Buy | $34.00 | N/A | Maintains | 2 years ago |
Verve Therapeutics IncVERV | 1 | Strong Buy | $55.00 | N/A | Maintains | 2 years ago |
Cymabay Therapeutics IncCBAY | 1 | Strong Buy | $20.00 | N/A | Initiates Coverage On | 2 years ago |
Arcturus Therapeutics Holdings IncARCT | 1 | Strong Buy | $36.00 | N/A | Reiterates | 3 years ago |
Mineralys Therapeutics IncMLYS | 1 | Strong Buy | $32.00 | N/A | Initiates Coverage On | 3 years ago |
Dice Therapeutics IncDICE | 1 | Strong Buy | $65.00 | N/A | Initiates Coverage On | 3 years ago |
Bristol Myers Squibb CoBMY | 5 | Hold | N/A | N/A | Downgrades | 3 years ago |
Altimmune IncALT | 2 | Strong Buy | $26.00 | N/A | Maintains | 3 years ago |
Albireo Pharma IncALBO | 1 | Strong Buy | $55.00 | N/A | Initiates Coverage On | 3 years ago |
Invivyd IncIVVD | 2 | Hold | N/A | N/A | Downgrades | 4 years ago |
Novartis AgNVS | 3 | Hold | N/A | N/A | Downgrades | 6 years ago |
Dermira IncDERM2 | 1 | Hold | N/A | N/A | Downgrades | 6 years ago |
Tesaro IncTSRO | 4 | Hold | $75.00 | N/A | Downgrades | 7 years ago |
Intra Cellular Therapies IncITCI | 3 | Buy | $27.00 | N/A | Initiates Coverage On | 7 years ago |
Allergan PLCAGN | 3 | Buy | $220.00 | N/A | Initiates Coverage On | 7 years ago |
Aclaris Therapeutics IncACRS | 1 | Buy | $54.00 | N/A | Maintains | 8 years ago |
Celldex Therapeutics IncCLDX | 2 | Hold | $45.00 | N/A | Maintains | 8 years ago |
Astrazeneca PLCAZN | 2 | Hold | $38.00 | N/A | Maintains | 8 years ago |
Pfizer IncPFE | 1 | Hold | $38.00 | N/A | Maintains | 8 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.